May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
Inflammatory Corneal Lymphangiogenesis is Inhibited by Blocking Vegfr3–Signalling
Author Affiliations & Notes
  • J. Onderka
    Augenklinik Erlangen, IZKF, Erlangen, Germany
  • F. Bock
    Augenklinik Erlangen, IZKF, Erlangen, Germany
  • T. Dietrich
    Augenklinik Erlangen, IZKF, Erlangen, Germany
  • B. Pytowski
    InClone, New York, NY
  • F. Kruse
    Augenklinik Erlangen, IZKF, Erlangen, Germany
  • C. Cursiefen
    Augenklinik Erlangen, IZKF, Erlangen, Germany
  • Footnotes
    Commercial Relationships  J. Onderka, None; F. Bock, None; T. Dietrich, None; B. Pytowski, InClone, E; F. Kruse, None; C. Cursiefen, None.
  • Footnotes
    Support  Interdisciplinary Center for Clinical Research (IZKF) Erlangen (A9)
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 3909. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Onderka, F. Bock, T. Dietrich, B. Pytowski, F. Kruse, C. Cursiefen; Inflammatory Corneal Lymphangiogenesis is Inhibited by Blocking Vegfr3–Signalling . Invest. Ophthalmol. Vis. Sci. 2006;47(13):3909.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Inflammatory corneal hem– and lymphangiogenesis occurring both prior to as well as after penetrating keratoplasty significantly increases the risk for subsequent immune rejections. Purpose of this study was to analyze whether the blocking anti–VEGFR3 antibody mF4–31C1 is able to inhibit the outgrowth of pathologic new lymphatic vessels in a mouse model of suture–induced, inflammatory corneal neovascularization. The potency of this antibody has been recently demonstrated in a mouse model of spontaneous, non–inflammatory corneal hem– and lymphangiogenesis.

Methods: : Three interrupted 11–0 nylon sutures were placed into the corneal stroma of BALB/c mice (6 weeks old) and left in place for seven days to induce neovascularization. The treatment group (n=9) received the anti–VEGFR3 antibody F4–31C1 intraperitoneally at day of surgery and three days later (0.5 mg/mouse). Control mice received an equal amount of control IgG solution (Jackson Immunoresearch, Inc. CA). For immunohistochemistry, corneal flat mounts were stained with LYVE–1 as a specific lymphatic vascular endothelial marker and CD31 as panendothelial marker. Morphometry was performed with the image analysis software analySIS^B (Soft Imaging Systems GmbH, Münster, Germany).

Results: : To improve the objectivity and precision of the morphometrical analysis, we established a modified analysing method using grey filter sampling on monochromatic pictures. The F4–31C1 antibody treated mice displayed nearly complete inhibition of lymphangiogenesis compared with IgG controls (p < 0.006).

Conclusions: : Inflammatory corneal lymphangiogenesis seems to depend on VEGFR3–signalling. By blocking this lymphangiogenic receptor the ingrowths of lymph vessels can be inhibited almost completely. This specific anti–VEGFR3 antibody could be used to inhibit lymphangiogenesis after keratoplasty to reduce neovascularization and thereby promote graft survival.

Keywords: cornea: clinical science • neovascularization • growth factors/growth factor receptors 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.